The research team, led by Naoya Kase and Yohsuke Harada, tackled a technical problem that has hampered the field for years. The defining feature of a regulatory T cell is its expression of a transcription factor called Foxp3, the master switch that establishes and maintains the cell’s identity. But if you experimentally delete the Foxp3 gene to study what happens, the protein disappears, and along with it any reliable way to label and track the cell. Conventional markers fail, and the cell becomes essentially invisible to the tools immunologists normally use to isolate specific cell populations for analysis.

To solve this, the researchers engineered a clever workaround using a bacterial artificial chromosome transgene. This engineered DNA segment drives expression of three useful proteins, green fluorescent protein, luciferase, and the diphtheria toxin receptor, under the control of the Foxp3 promoter. Crucially, this reporter operates independently of the endogenous Foxp3 locus, so even after the native gene is deleted with tamoxifen, the cells continue to glow green. The team validated the system carefully, showing that after tamoxifen treatment the frequency of cells detectable by antibody staining for Foxp3 dropped sharply while the fluorescent population persisted, and that most fluorescent cells retained canonical Treg features such as high CD25 expression and enriched CTLA-4.

The mouse model at the heart of the study is distinctive in another important respect. Rather than inducing eczema-like disease with an external chemical irritant, as in the widely used MC903 model, the researchers deleted two genes, Foxp3 and Bcl6, whose combined loss triggers spontaneous development of atopic dermatitis-like skin inflammation roughly two weeks after deletion. That timing window is a major advantage, because it allows scientists to observe molecular changes in immune cells as they unfold before any visible disease appears, something impossible in models where dermatitis erupts almost immediately.

When the team sequenced the RNA of fluorescent cells sorted from the spleens of these mice fourteen days after starting tamoxifen treatment, the results contained a genuine surprise. The combined deletion produced a signature of 144 genes specifically upregulated in the double-deficient Tregs, and gene ontology analysis revealed an unexpectedly strong enrichment of antiviral and type I interferon response programs. Type I interferons are classically associated with the body’s first line of defense against viruses, not with the type 2 allergic inflammation that defines eczema. Further gene set enrichment analysis comparing single and double knockout cells confirmed the pattern, and most interferon-alpha response genes showed their highest expression in the double-deficient group.

The researchers then asked whether Bcl6 loss alone could explain the interferon signature, since BCL6 is known to act as a transcriptional repressor that tamps down antiviral programs in other immune cell types. Reanalysis of an existing public dataset comparing Bcl6-deficient and wild-type Tregs showed that the interferon-related gene ontology terms were not significantly enriched in Tregs lacking only Bcl6. This indicated that losing Bcl6 by itself is not enough. Instead, the simultaneous disruption of both Foxp3-dependent and Bcl6-dependent transcriptional control appears to create a permissive state in which the interferon-associated program can emerge in this cell lineage.

The pivotal question was whether this mouse signature had any bearing on actual human disease. To find out, the team reanalyzed publicly available single-cell RNA sequencing data from the peripheral blood of atopic dermatitis patients and healthy controls. After careful quality control, batch correction with Harmony, and clustering of the T cell compartment into nine distinct subsets, they converted 102 of the mouse signature genes into their human orthologs and computed signature scores for each cell type. The result was striking: the mouse-derived signature was substantially and selectively elevated in the regulatory T cell population of patients, while other T cell subsets showed far less enrichment. A parallel analysis using a canonical type I interferon response gene set produced the same disease-specific pattern in Tregs.

Digging deeper into the regulatory architecture, the researchers used a computational tool called ChEA3 to identify upstream transcription factors likely driving the upregulated genes, and then applied SCENIC, a single-cell regulatory network inference method, to the patient data. Nine of the top twenty predicted factors could be detected as active regulons in human Tregs, and most of these were preferentially enriched in patient cells compared with healthy controls. The standouts were a coherent cast of interferon-associated regulators: IRF7, IRF9, STAT1, and STAT2, along with BATF3. This network maps precisely onto the canonical type I interferon pathway, in which interferon signaling through the JAK-STAT cascade assembles an ISGF3 complex of STAT1, STAT2, and IRF9 to activate interferon-stimulated genes, with IRF7 serving as a key amplifier of the antiviral program.

Context matters enormously here, and the authors are careful on this point. Type I interferons have a complicated relationship with atopic dermatitis. Patients with eczema are famously susceptible to viral skin infections such as eczema herpeticum, and plasmacytoid dendritic cells, the skin’s major interferon producers, are markedly reduced in diseased skin. Animal work has even shown that interferon produced by a specific monocyte subset suppresses type 2 inflammation in eczema-like disease. Yet prior studies in other settings, including rhinovirus infection and chronic immune thrombocytopenia, have found that Tregs acquiring an interferon-responsive transcriptional state lose suppressive capacity. The new findings suggest that interferon-related responses in atopic dermatitis may differ sharply between cell types, with Tregs shifting into an interferon-high state even as antiviral defense elsewhere is weakened. Whether this program actually causes Treg dysfunction in patients remains unproven, since suppressive activity was not directly measured in the human cells analyzed.

The study carries clear limitations that temper its conclusions. About ten percent of the fluorescent cells in untreated mice were Foxp3-negative, so a minor non-Treg contribution to the profiles cannot be excluded. The fluorescent cells were detected in inflamed skin, but their causal role in driving dermatitis was not established, and the human analysis was restricted to atopic dermatitis, leaving open whether the interferon-high Treg state is unique to eczema or common across inflammatory skin diseases. Even so, the work delivers something the field has lacked: a genetically defined, temporally controllable animal model whose Treg transcriptional state, upstream regulators and all, mirrors what is found in patient cells. If future experiments confirm that this interferon-associated state drives functional defects in Tregs, it could open a genuinely new therapeutic angle for a disease currently dominated by antibody drugs that carry ocular side effects and heavy costs.

Subject of Research: Type I interferon-associated transcriptional changes in regulatory T cells in atopic dermatitis

Article Title: Cross-species gene expression analysis identifies a type I interferon-associated transcriptional signature in Tregs from atopic dermatitis

Article References: Kase, N., Nakamura, H., Nakakomi, C., Shimakata, M., Banno, M., Kanari, R., & Harada, Y. (2026). Cross-species gene expression analysis identifies a type I interferon-associated transcriptional signature in Tregs from atopic dermatitis. Journal of Cutaneous Immunology and Allergy, 9, Article 17310. https://doi.org/10.3389/jcia.2026.17310

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.17310

Keywords: atopic dermatitis, regulatory T cells, Foxp3, Bcl6, type I interferon, transcriptional signature, single-cell RNA sequencing, IRF7, STAT1, mouse model, immune tolerance, eczema

The team built its case on single-cell transcriptomics. Using both single-cell and single-nucleus RNA sequencing, the researchers generated a high-resolution cellular map of the mouse and human mediobasal hypothalamus, then integrated the two datasets computationally in a shared latent space to compare tanycytes across species. The integration workflow, based on deep generative models and probabilistic label transfer, allowed them to annotate eight tanycyte subclusters in the human tissue that correspond to subclusters defined in the mouse. Among these, one subcluster stood out. In both species, the T8 tanycyte state was enriched for genes associated with innate immunity, showing robust activation of interferon-α and interferon-γ response pathways and expression of downstream interferon-stimulated genes. In other words, a cell type conventionally classified as glia carries a transcriptional programme that resembles an immune cell state, and this programme is conserved between mouse and human hypothalamus.

What makes the finding striking is its dynamics. In female mice, the abundance and activity of this immune-associated tanycyte state changed across the oestrous cycle. The researchers captured sex-, oestrous cycle- and high-fat diet-dependent transcriptomic shifts in tanycytes, and found a cyclic expression of the gene encoding interferon regulatory factor 7 (Irf7), a master transcription factor of the interferon signalling family, together with downstream interferon-stimulated genes such as Cxcl10, a chemokine that recruits leukocytes. Spatial validation by RNAscope fluorescent in situ hybridization showed that Irf7 mRNA transcripts concentrated in defined ventricular regions of the arcuate nucleus and median eminence, and that regions containing CD45-high infiltrating leukocytes spatially coincided with zones of elevated Irf7 and Cxcl10 expression. In physiological males, by contrast, Irf7 expression in tanycytes remained stable and markedly lower, suggesting that cycling females mount a distinct pattern of immune activation in the brain that is tied to the changing hormonal milieu of the cycle, particularly oestradiol.

The mechanistic thread connecting oestradiol to interferon signalling runs through kinases. Upstream kinase analysis of oestradiol-regulated phosphosites in tanycytes identified TBK1 and IKKε, the canonical kinases that phosphorylate IRF7, as top hits with negative kinase statistics and high specificity scores, indicating that oestradiol treatment suppresses the activity of these IRF7-activating kinases. At the same time, imaging of NF-κB reporter mice revealed that κ-EGFP-positive tanycytes in the arcuate nucleus and median eminence increased at oestrus compared with diestrus, and that vimentin-stained tanycyte processes contacted κ-EGFP-positive microglia and CD45-positive immune cell complexes near vessels. Oestradiol thus appears to engage both the NF-κB and interferon regulatory signalling axes in tanycytes and in the immune cells of the median eminence, positioning these glial cells as integrators of endocrine and inflammatory signals at the brain’s metabolic gateway.

To test whether this cyclic immune programme matters functionally, the team manipulated oestrogen and interferon signalling in tanycytes. Ovariectomy with and without oestradiol replacement altered serum oestradiol levels and changed tanycytic IRF7 activity and leukocyte infiltration into the median eminence. The data support a model in which balanced, cyclic leukocyte infiltration into the median eminence may have a role in maintaining the oestrous cycle itself. This is a provocative idea: rather than viewing immune cell traffic across the permeable median eminence as pathological inflammation, the study suggests that a controlled, hormone-gated influx of leukocytes could be part of the physiological machinery that supports reproductive cycling, with tanycytes orchestrating the timing through interferon-dependent chemokine release.

The reach of tanycytic IRF7 extends beyond the brain. By selectively depleting Irf7 in tanycytes using an adeno-associated viral vector carrying an Irf7 short hairpin RNA, delivered into the lateral ventricle with a Dio2 promoter-driven Cre recombinase that restricts recombination to tanycytes, the researchers generated mice with tanycyte-specific Irf7 knockdown. RNAscope quantification confirmed the reduction of Irf7 mRNA transcripts in the knockdown animals. Flow cytometry of circulating blood then revealed that Irf7 in tanycytes modulates the proportions of circulating monocytes, the classical, intermediate and non-classical subsets that patrol vessels and migrate into tissues. Neutrophils, eosinophils, natural killer cells and T cell populations were unchanged, indicating a selective effect on the monocyte compartment. The finding provides direct evidence of brain-to-immune system communication through tanycytes, echoing earlier work showing that hypothalamic sensing of metabolic state regulates circulating monocytes.

How could glial cells lining a brain ventricle influence the blood immune compartment? The most plausible route lies in the anatomy of the median eminence, where tanycytes form the blood–hypothalamus barrier and contact both the portal vasculature and the cerebrospinal fluid. Tanycytes release chemokines such as CXCL10 in an interferon-dependent manner, and their processes extend toward vessels and immune cell complexes in the arcuate nucleus. Signalling through this interface could alter the cytokine milieu that reaching monocytes encounter, or modify endothelial and perivascular cues that determine monocyte egress from the bone marrow and patrolling behaviour in the bloodstream. The study also documented cyclic cytokine responses, with serum concentrations of inflammatory cytokines measured across the oestrous cycle, and found that interferon-γ pathway components, including Ifng, Tbx21 and the interferon-γ receptor subunits, were expressed in the mediobasal hypothalamus, providing potential ligand–receptor pairs that could drive the tanycytic interferon programme during the cycle.

The cross-species dimension of the work strengthens its relevance to human biology. Human tanycyte subclusters predicted by the computational integration showed the same enrichment of interferon-α and interferon-γ response pathways and interferon-stimulated gene expression in the human T8 state as in the mouse. The human samples came from single-nucleus sequencing of the mediobasal hypothalamus of donors, including donors with Alzheimer’s disease, frontotemporal dementia, type 2 diabetes and chronic myelomonocytic leukemia, and the descriptive analyses showed that the immune-associated tanycyte state was present across sexes and pathological conditions. Because sex-biased differences in metabolic and immune function are shaped by endocrine–immune interactions, the identification of a conserved, hormone-responsive immune programme in tanycytes offers a cellular substrate for understanding why many inflammatory, metabolic and neurodegenerative diseases show sex-biased incidence and progression.

Technically, the study exemplifies the current generation of single-cell neuroscience. The researchers used scVI-based deep generative modelling to integrate mouse and human datasets, scANVI for probabilistic label transfer of tanycyte subclusters, SCENIC for transcription factor regulon inference that identified the Irf7 regulon and its two target subnetworks enriched for innate immune and interferon-related functions and for antigen presentation and leukocyte activation, and scProportionTest with permutation-based cell-level statistics to quantify changes in subcluster abundance between conditions. Spatial transcriptomic validation with published hypothalamic atlases and RNAscope in situ hybridization anchored the cell states to defined anatomical zones along the anteroposterior axis of the third ventricle. Kinome assays with serine–threonine phosphosite analysis connected oestradiol to the IRF7 phosphorylating kinases. The combination of computational and spatial methods, together with physiological follow-up of body weight, fat mass and blood glucose in the sequenced animals, gives the findings a solid technical footing.

The implications reach toward several frontiers. If cyclic interferon signalling in tanycytes gates leukocyte traffic into the median eminence and shapes circulating monocyte proportions, then disruptions of this programme, whether by chronic high-fat diet, by loss of ovarian hormones, or by pathological inflammation, could alter both reproductive function and systemic immune regulation. The study’s observation that high-fat diet feeding changed tanycytic transcriptomic states, and that the immune-associated state responded to diet and cycle in combination, suggests that metabolic disease may reprogramme the brain’s immune interface. Conversely, the tanycyte degeneration linked to impaired tau clearance in recent work hints that these cells also participate in neurodegenerative pathology. By revealing an immune-associated role for tanycytes and a conserved, oestradiol-responsive IRF7 programme that communicates between brain, body and immune system across the ovarian cycle, the study opens a new chapter in neuroendocrine immunology, one in which the glial border of the metabolic brain is not merely a barrier but an active, hormone-gated immune organ.

Subject of Research: IRF7 signalling in tanycytes controls brain–body–immune response across the ovarian cycle

Article Title: IRF7 signalling in tanycytes controls brain–body–immune response across the ovarian cycle

Article References: Nampoothiri, S., Fernandois, D., Journiac, N., Delahaye, F., Mbouamboua, Y., Sauve, F., Couralet, M., Gallet, S., Mroueh, N., Serradas Aponte, M. L., Jouy, N., Spenle, R., Schmidt-Ullrich, R., Corral, I. M., Mattot, V., Almodovar, C. R. D., Schlitzer, A., Froguel, P., Maurage, C.-A., … Prevot, V. (2026). IRF7 signalling in tanycytes controls brain–body–immune response across the ovarian cycle. Nature Metabolism. https://doi.org/10.1038/s42255-026-01635-4

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01635-4

Keywords: IRF7, signalling, tanycytes, controls, brain, body, immune, response, across, ovarian, cycle, scientific research

Systemic lupus erythematosus is a complex autoimmune disease in which the immune system turns against the body’s own tissues, attacking the skin, joints, kidneys, blood cells, and other organs with chronic inflammation. Genetics plays a substantial role in determining who develops lupus, and many of the genetic regions associated with disease risk have been catalogued for years through large-scale association studies. A major challenge, however, has been moving from statistical association to biological mechanism. Knowing that a stretch of DNA correlates with disease risk says little about what the inherited variant actually does inside immune cells, or why it increases susceptibility not just to lupus but frequently to several autoimmune conditions at once. The new study addresses that gap directly by dissecting what one of the most prevalent lupus-risk haplotypes does to the function of IRF7, a gene whose protein product orchestrates the production of type I interferons, the chemical alarm signals that mobilize antiviral defense throughout the body.

IRF7 helps cells respond to viral infection by activating the production of type I interferons, most notably interferon-alpha, or IFN-α. These signaling molecules are essential components of innate immunity, spreading rapidly from infected cells to their neighbors and instructing them to enter a defensive state that makes viral replication far more difficult. But type I interferon signaling has long been strongly implicated in lupus as well. Many patients with lupus carry a chronically elevated interferon activity in their blood, a phenomenon so consistent that researchers refer to it as the ‘interferon signature,’ and therapies designed to block this pathway have already been approved for treating the disease. The Cincinnati Children’s team reasoned that the connection between these two observations, effective antiviral defense on one side and pathological interferon activity on the other, might run through the genetic variation within IRF7 itself.

That reasoning proved correct. The researchers found that the lupus risk haplotype increases IRF7-dependent induction of IFN-α. In practical terms, individuals carrying this common genetic configuration mount a stronger interferon response under the conditions studied, meaning their antiviral alarm system can ring louder and faster when a viral threat is detected. That heightened responsiveness can be a genuine asset in fighting infection. Yet the very same biology can also promote excessive or inappropriate immune activation, tipping the balance of the immune system toward the self-directed inflammation that defines lupus. The study thereby exposes what the authors describe as an important biological tradeoff, in which a single inherited configuration of the immune system confers both an advantage and a vulnerability depending on context.

The evolutionary implications are striking. A more vigorous antiviral immune response may have been enormously beneficial throughout human history, particularly during eras when infectious diseases represented one of the greatest threats to survival. Populations in which individuals responded more forcefully to viral invasion may have withstood epidemics that devastated others. But an immune system that is especially sensitive to viral signals also carries a greater inherent tendency to cross the line from protective immunity into autoimmunity. The new findings therefore suggest that at least some lupus risk variants should not be thought of as ‘defective’ versions of immune genes at all. Instead, they represent versions of the immune system that simply perform differently, offering an advantage in one environment while increasing disease susceptibility in another. This reframing helps explain why such variants remained common: natural selection may have favored them precisely because of the very biology that now contributes to autoimmune disease.

Sam Virolainen, PhD, first author of the study and a graduate of the Immunology Graduate Program at Cincinnati Children’s, said the findings help explain why a genetic variant linked to lupus remained so common and how, biologically, it affects the immune system more broadly. Reflecting on the training that shaped the work, Virolainen noted an appreciation gained during doctoral research in the Kottyan and Weirauch laboratories that many genetic risk factors can contribute to multiple diseases, especially when the immune system is involved. That multiscale perspective, spanning molecular regulation, cellular signaling, and population genetics, is evident throughout the study’s design and interpretation, and it underscores how a variant’s effect can ripple across very different levels of biological organization.

The work also feeds into a larger and still-unresolved question: how inherited genetic risk interacts with viral infection in the development of autoimmunity. For years, researchers have recognized a strong relationship between Epstein-Barr virus, or EBV, and lupus. Nearly everyone is exposed to EBV at some point in their lives, yet only a small fraction of those exposed ever develop lupus. Genetics may help explain why the consequences of the same viral exposure differ so dramatically from one person to the next. The research team’s previous work examined how viral proteins, including those produced by EBV, interact with the human genome at regions associated with autoimmune disease. The new IRF7 study approaches the gene-virus relationship from the opposite direction. Rather than asking how a virus interacts with genetically susceptible cells, the team asked how inherited genetic variation changes the antiviral response itself, and the answer places both processes on converging molecular roads.

‘Together, these studies support a model in which genetic susceptibility and viral exposure are not independent risk factors. They can converge on the same regulatory pathways,’ said Kottyan. In this model, a person’s inherited genome shapes how strongly their immune system reacts to infection, while viral infection in turn activates molecular pathways that are already tuned by that genetic makeup. In some individuals, the interaction of the two may explain how an ordinary antiviral immune response develops into chronic autoimmune inflammation. The lupus-risk IRF7 haplotype amplifies the interferon arm of this convergence, but the principle likely extends to other immune genes and other autoimmune conditions, offering a framework in which genetics and environment are treated as intertwined rather than separate contributors to disease.

The study does not immediately change how lupus is diagnosed or treated, and carrying this genetic haplotype does not mean that someone will develop the disease. Lupus arises from the combined effects of many genetic variants together with environmental exposures and other biological factors, and no single inherited element is decisive on its own. However, the research demonstrates how scientists can move beyond simply identifying genetic risk factors to understanding, at a mechanistic level, how those variants alter immune function. Studies of this kind help build a foundation for future research into what drives disease and why its course differs from person to person. ‘I am hopeful that our work will increase our understanding of not just lupus biology but other diseases with similar genetic and immunologic complexities,’ said Virolainen. Many disease-associated variants have already been identified, but their biological effects remain unclear. By clarifying the molecular pathways involved, the Cincinnati Children’s team and their collaborators, who spanned institutions across 13 U.S. states and territories and six countries, may ultimately help guide therapies that target disease more precisely while preserving the normal antiviral function that those same variants evolved to protect.

Subject of Research: Genetic and immunological mechanisms linking a common IRF7 haplotype to enhanced antiviral defense and increased lupus risk

Article Title: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics

Article References: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lupus, systemic lupus erythematosus, IRF7, interferon-alpha, autoimmunity, antiviral immunity, genetic haplotype, Epstein-Barr virus, transcription factor, immune genetics, Cincinnati Children's, interferon signature